If you're reading this, you're probably in one of three places: you've just been handed a prescription and you're wondering what the next few weeks look like, you're mid-titration and something doesn't feel right, or you've been told there's a two-year wait and you're trying to work out your options.
This guide covers what lisdexamfetamine actually does, what the first three months usually involve, and what to do when the medication is fine but the prescribing has fallen apart — which, in the UK, is the part that most often goes wrong.
Everything clinical here follows the UK Summary of Product Characteristics. It's information, not a recommendation: whether any ADHD medication is right for you is a decision for you and a prescriber who has assessed you.
Where are you right now?
- Just started, or about to start. What the first 12 weeks involve →
- On it, but something's off. Side effects and dose problems →
- Diagnosed, but no one is prescribing. Discharged, clinic closed, shared care refused, or stuck on a waiting list. How to restart specialist prescribing →
How lisdexamfetamine works
Lisdexamfetamine is a prodrug. The capsule itself is inactive — it's lisdexamfetamine attached to the amino acid lysine. Once swallowed, it's converted in the blood to dexamfetamine, which is the part that does the work.
Dexamfetamine increases the availability of dopamine and noradrenaline in the brain, the two neurotransmitters most involved in attention, motivation, working memory and impulse control.
Because the conversion is enzymatic and gradual, the rise is slower and flatter than an immediate-release stimulant. Peak plasma concentration is reached around 3 to 4 hours after dosing in adults, and effects were still measurable at 14 hours in adult clinical studies. In practice, that means most people take it once in the morning and don't need a top-up dose.
What it's licensed for in the UK
In the UK, lisdexamfetamine is licensed for ADHD:
In adults, as part of a comprehensive treatment programme, where ADHD symptoms were present in childhood.
In children aged 6 and over, as part of a comprehensive treatment programme, where the response to previous methylphenidate treatment has been clinically inadequate.
Two phrases in that licence do a lot of work and are worth taking seriously.
"Part of a comprehensive treatment programme." Medication is one component. The licence assumes it sits alongside psychological, educational or workplace support — not instead of it.
Specialist supervision. Treatment must be initiated under the supervision of a specialist in ADHD, with cardiovascular assessment before starting and monitoring throughout. This isn't a formality; it's the reason a prescription can't simply be moved to a GP without a specialist behind it.
In the United States, lisdexamfetamine also carries a licence for moderate-to-severe binge eating disorder in adults. That indication does not apply in the UK, and prescribing for it here would be off-label.
This is the part almost no one explains properly, and it's where most people either settle or give up.
Titration is not "trying the medication". It is a structured process of finding the lowest dose that gives you a meaningful response with tolerable side effects, with objective safety monitoring at every step. Done properly in adults it usually runs something like this:
Before the first dose. Baseline blood pressure, pulse, height and weight. A cardiac history — personal and family. Any history of structural heart disease, arrhythmia, unexplained fainting, or sudden cardiac death in a relative under 40 needs to be picked up before a stimulant is started, not after.
Weeks 1–2: starting dose. Usually a low starting dose taken in the morning. You're looking for signal, not perfection. Most people notice something within the first few days; some notice very little at the starting dose, which is normal and not a failure.
Weeks 2–8: stepping up. Doses are increased in increments, typically no faster than weekly, with blood pressure and pulse rechecked after each change and appetite, sleep and mood tracked. This is why home monitoring matters — a dose change made without a reading is a guess.
Weeks 8–12: settling. Once you've found a dose that works, the pattern of the day matters more than the peak: when it comes on, when it wears off, whether the evening is manageable, whether you're eating and sleeping.
Then: ongoing review. Once stable, review moves to periodic — but it doesn't stop. Blood pressure, pulse, weight and response are checked at intervals for as long as you're on treatment.
Things that commonly go wrong in titration
Going up too fast. More side effects, no more benefit, and you can't tell which dose was the good one.
Stopping at the first dose that does something. "Better than nothing" is not the same as optimised.
No objective monitoring. Without blood pressure and pulse readings, a prescriber is working blind and will usually be conservative — which means an under-treated patient.
Gaps between appointments. A four-week wait for a dose review turns a 12-week titration into a nine-month one.
Judging it in a bad fortnight. Sleep debt, illness, or a heavy work period will all blunt the picture.
Titration support
Titration stalled, or never really started?
Focus Gently is a CQC-registered remote adult ADHD service. If you already have a UK diagnosis, we can review your existing report and take over specialist prescribing, titration and monitoring — dose reviews when you need them, not when the next slot happens to be free.
- Free review of your existing diagnostic report
- £89/month, all reviews and prescriptions included — no joining fee, no per-appointment charge
- Cancel any time; we request shared care from your GP each year
A UK diagnosis and a home blood pressure monitor are required. Medication is dispensed and charged separately by our partner pharmacy.
Listed as very common (affecting more than 1 in 10 people) in the UK product information:
Decreased appetite
Difficulty sleeping
Dry mouth
Headache
Upper abdominal pain
Weight loss
Most of these are most pronounced in the first few weeks and settle for many people. Appetite and sleep are the two that most often drive a dose change.
Also reported: increased heart rate and blood pressure, anxiety, irritability, low mood as the dose wears off, nausea, and reduced libido.
Less common but important. Cardiovascular effects, significant mood changes, and psychotic symptoms are rare but real, and risk is higher where there's an underlying condition. Growth should be monitored in younger patients. Tell your prescriber about chest pain, breathlessness on exertion, fainting, new or worsening mood symptoms, or anything unusual — don't wait for the next scheduled review.
What to do about the common ones:
Appetite. Eat before the dose, not after. Protein-dense food and a real evening meal once it wears off.
Sleep. Usually about dose timing rather than dose size. Taking it later in the day is the most common cause.
Afternoon crash. Often a sign the dose is too high rather than too low.
Dry mouth. Water, and be aware of the dental implications over time.
None of these should be managed by adjusting your own dose. They're the reason review appointments exist.
How it compares to other ADHD medications
| Medication | How it works | Duration | Notes |
|---|---|---|---|
| Lisdexamfetamine (Elvanse, Vyvanse) | Prodrug; converted in the blood to dexamfetamine, which increases dopamine and noradrenaline | Up to ~14 hours in adults | Smooth onset and offset; once-daily; Schedule 2 controlled drug |
| Methylphenidate (Concerta XL, Xaggitin, Medikinet) | Blocks reuptake of dopamine and noradrenaline | 4–12 hours depending on formulation | Usually first-line in UK adult guidance; several modified-release formats with different release profiles |
| Dexamfetamine (Amfexa) | Increases dopamine and noradrenaline directly | 4–6 hours | Short-acting; often needs twice-daily dosing |
| Atomoxetine (Strattera) | Non-stimulant; selective noradrenaline reuptake inhibitor | Continuous, once daily | Takes several weeks for full effect; not a controlled drug; UK shared care protocols commonly require liver function checks |
| Guanfacine (Intuniv) | Non-stimulant; selective alpha-2A agonist | Continuous, once daily | Licensed in the UK for ages 6–17 only — any adult use is off-label. Requires blood pressure and pulse monitoring |
On first-line choice: UK guidance generally puts methylphenidate first for adults, with lisdexamfetamine where methylphenidate has been tried and hasn't worked well enough or isn't tolerated. Individual circumstances vary — this is a clinical decision, not a preference.
Misuse, storage and controlled drug status
In the UK, lisdexamfetamine is a Schedule 2 controlled drug. That has practical consequences you'll notice:
Prescriptions are usually limited to 30 days' supply.
A prescription must be dispensed within 28 days of the date on it.
There is no repeat-prescription-on-tap; each script is issued individually.
Many private services, including ours, cannot hand you a paper script for a local pharmacy — Schedule 2 prescriptions are sent directly to a registered dispensing pharmacy and tracked to you.
Storage. Keep it somewhere secure, particularly in a shared house or where there are teenagers or children. Stimulant diversion is common and it is your prescription and your responsibility.
Misuse. The prodrug design means it has to be metabolised before it becomes active, which reduces — but does not remove — the potential for misuse. Taking more than prescribed carries real cardiovascular and psychiatric risk. Dose changes go through your prescriber.
What it costs in the UK
On the NHS: you pay the standard prescription charge per item, or nothing if you're exempt. A prepayment certificate is worth checking if you have multiple regular items.
Privately: two separate costs, and conflating them is where most people get confused.
The medication, dispensed and charged by a pharmacy. Lisdexamfetamine currently runs to roughly £100 a month at typical adult doses; methylphenidate formulations are usually lower, around £50.
The clinical care — the specialist review, titration, monitoring and the prescription itself. At Focus Gently this is £89 a month, with no joining fee and no charge per appointment.
On shared care. If your GP agrees to a shared care arrangement, NHS prescribing can take over the medication cost while a specialist retains oversight. GP practices are not obliged to agree, and many now decline. It's worth asking; it's not worth counting on.
When the medication is fine but the prescribing isn't
This is the most common reason UK adults end up without treatment, and it has nothing to do with the drug working.
The usual routes in:
Discharged from an NHS service after titration, with shared care refused by the practice — leaving nobody prescribing.
A private provider closed, or was suspended, and records went with it.
Shared care declined from the outset, so a private prescription continues indefinitely at private cost.
A waiting list measured in years for an assessment or for medication review.
Moved area, and the new ICB won't accept the previous arrangement.
In all of these, you have a valid UK diagnosis and a known effective dose. What's missing is a prescriber willing to hold clinical responsibility, monitor you, and issue the script.
Transfer of care
Already diagnosed in the UK, but no one is prescribing?
Send us your existing diagnostic report. We'll review it free of charge and tell you honestly whether we can take over your care — and if we can't, why not.
- Free 15-minute call with a prescriber, no obligation
- Specialist review, titration, monitoring and prescriptions for £89/month
- Annual shared care request to your GP, so you have a route back to NHS prescribing
- Unlimited reviews — no charge for needing an extra appointment
We can only accept diagnoses made in the UK. Assessments carried out abroad need a UK reassessment before we can prescribe.
Frequently asked questions
How long does it take to work? You may notice something in the first few days, but the starting dose is rarely the effective dose. Judge it over a titration of roughly 8–12 weeks, not over a week.
Can I take it every other day, or skip weekends? Speak to your prescriber. Planned breaks are sometimes appropriate and sometimes counterproductive, and it depends on why you're considering it.
Will my GP prescribe it? Only under a shared care agreement with a specialist, and only if your practice accepts one. Many no longer do.
Can I get it prescribed privately if I was diagnosed on the NHS? Yes, provided the diagnosis was made in the UK and the documentation is adequate. That's what a report review establishes.
Does it stop working over time? Genuine tolerance is less common than people assume. More often, a dose that was never fully optimised is being tested by a harder period. That's a review conversation.
Can I drive on it? Prescribed stimulants are covered by the medical defence in UK drug-driving law when taken as prescribed. Carry evidence of your prescription. If you feel impaired, don't drive.
Why do I have to collect it every month? Schedule 2 controlled drug rules limit supply to 30 days and require dispensing within 28 days of the prescription date.
The bottom line
Lisdexamfetamine works well for a lot of adults, and the once-daily, smooth-release design suits people who've struggled with the peaks and troughs of shorter-acting stimulants. But the medication is the easy part. What determines whether treatment actually works is titration done patiently with real monitoring, and a prescriber who's still there in six months.
If that's the part that's broken for you, it's fixable.
Not diagnosed yet? Start with an adult ADHD assessment → · Just researching? Get our monthly ADHD briefing →
Written and clinically reviewed by Jeffrey Lacanlale, RN Independent Prescriber (NMC 10J0035O), Registered Manager, Acute Care Direct Limited trading as Focus Gently. CQC Provider ID 1-24764609935. Last reviewed 20/9/26. This article is general information about a prescription-only medicine and is not a recommendation to use it; treatment decisions require an individual assessment by a qualified prescriber.
Sources: UK Summary of Product Characteristics for Elvanse (electronic medicines compendium); NICE NG87, Attention deficit hyperactivity disorder: diagnosis and management.
